Novartis, Mylan Settle Feud Over Generic Vivelle-Dot
Drugmakers Novartis AG and Mylan Inc. have settled patent litigation over Mylan's bid to produce a generic version of Novartis' estrogen therapy drug Vivelle-Dot, which will allow the generic to be...To view the full article, register now.
Already a subscriber? Click here to view full article